Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TSHR antagonist S37a is a selective antagonist of thyrotropin receptor (TSHR), with potential for the treatment of Graves' orbitopathy.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 476.00 | |
25 mg | 6-8 weeks | $ 1,530.00 | |
50 mg | 6-8 weeks | $ 1,990.00 | |
100 mg | 6-8 weeks | $ 2,980.00 |
Description | TSHR antagonist S37a is a selective antagonist of thyrotropin receptor (TSHR), with potential for the treatment of Graves' orbitopathy. |
In vitro | In HEK293 cells, TSHR antagonist S37a is an inhibitor of TSHR(IC50s of 40 μM and approximately 20 μM for mTSHR and hTSHR, respectively). TSHR antagonist S37a also activation by monoclonal TSAb M22 (human), KSAb1 (murine), and the allosteric small-molecule agonist C2. |
In vivo | In GO patients' sera, TSHR antagonist S37a inhibits cyclic adenosine monophosphate formation by oligoclonal TSAb, which are highly enriched. |
Molecular Weight | 460.57 |
Formula | C25H20N2O3S2 |
CAS No. | 2143452-20-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TSHR antagonist S37a 2143452-20-2 Others TSHR antagonist S-37a inhibitor inhibit